

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

Final Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company	<u>General</u>
Pfizer (marstacimab)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Beacon	Board of Community Health Councils in
Black Health Agency for Equality	Wales
Gene People	 British National Formulary
Genetic Alliance UK	Care Quality Commission
Haemophilia Alliance	Cell and Gene Therapy Catapult
South Asian Health Foundation	Department of Health, Social Services
Specialised Healthcare Alliance	and Public Safety for Northern Ireland
The Haemophilia Society	Haemophilia Northern Ireland
,	Haemophilia Scotland
Healthcare professional groups	Haemophilia Wales
Association of Genetic Nurses &	Healthcare Improvement Scotland
Counsellors	Hospital Information Services -
British Blood Transfusion Society	Jehovah's Witnesses
British Committee for Standards in	Medicines and Healthcare Products
Haematology	Regulatory Agency
British Geriatrics Society	 National Association of Primary Care
British Paediatric Allergy, Immunity	National Pharmacy Association
and Infection Group	NHS Alliance
British Society for Gene and Cell	NHS Confederation
Therapy	 Scottish Medicines Consortium
British Society for Genetic Medicine	Welsh Government
British Society for Haematology	 Welsh Health Specialised Services
British Society for Immunology	Committee
Haemophilia Chartered	
Physiotherapists Association	Comparator companies
Haemophilia Nurses Association	 Bio Products Laboratory (factor IX,
Royal College of General Practitioners	factor VIII)
Royal College of Nursing	 CSL Behring (etranacogene
Royal College of Pathologists	dezaparvovec, factor IX, factor VIII)
Royal College of Physicians	 Grifols UK (factor IX, factor VIII)
Royal Pharmaceutical Society	 Novo Nordisk Ltd (factor VIII, eptacog
Royal Society of Medicine	alfa, nonacog beta pegol, turoctocog
UK Clinical Pharmacy Association	alfa pegol)

Final stakeholder list for the evaluation of marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]



Consultees	Commentators (no right to submit or appeal)
UK Forum on Haemoglobin Disorders UK Haemophilia Centre Doctors' Organisation (UKHCDO) Others Department of Health and Social Care NHS England	 Octapharma (factor VIII, simoctocog alfa) Pfizer (fidanacogene elaparvovec, moroctocog alfa, nonacog alfa) Roche products (emicizumab) Swedish Orphan Biovitrum (efanesoctocog alfa, efmoroctocog alfa, eftrenonacog alfa) Takeda (factor IX, factor VIII, octocog alfa, rurioctocog alfa pegol, susoctocog alfa)
	 Relevant research groups Cochrane Cystic Fibrosis & Genetic Disorders Group Cochrane Haematology Cochrane UK Genomics England Haemnet MRC Clinical Trials Unit National Institute for Health Research NHS Oxford Haemophilia and Thrombosis Centre NHS Southern Haemophilia Network Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final stakeholder list for the evaluation of marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

Issue date: May 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.